ELOQUENT-2: Lenalidomide and dexamethasone with or without elotuzumab in relapsed/refractory multiple myeloma | Dr Joseph Mikhael at ASCO 2015

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph R. Mikhael, MD, of Mayo Clinic, Scottsdale, AZ, discusses the results of the phase 3 ELOQUENT-2 trial of lenalidomide an... Author: EMJ Added: 07/20/2015
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts